Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 7/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.45 |
| ▸ | HTR4 | Q13639 | 7/20 | 0.44 |
| ▸ | HTR3A | P46098 | 5/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17437965 | 0.90 | ROCK1 (0.45) | ROCK1ROCK2HTR4HTR3A | |
| SCHEMBL19902363 | 0.85 | ALDH1A1 (0.53) | ROCK1HTR4HTR3A | |
| SCHEMBL19902382 | 0.80 | ROCK1 (0.54) | ROCK1ROCK2HTR4HTR3A | |
| SCHEMBL19902367 | 0.79 | ROCK1 (0.51) | ROCK1ROCK2HTR4HTR3A | |
| SCHEMBL17437985 | 0.76 | ROCK1 (0.55) | ROCK1ROCK2HTR4HTR3A | |
| SCHEMBL17437931 | 0.75 | ALDH1A1 (0.48) | ROCK1ROCK2HTR4HTR3A | |
| SCHEMBL19902475 | 0.71 | ROCK2 (0.47) | ROCK1ROCK2 | |
| SCHEMBL17452673 | 0.71 | ROCK2 (0.49) | ROCK1ROCK2HTR4HTR3A | |
| SCHEMBL19902350 | 0.71 | ALDH1A1 (0.57) | ROCK1ROCK2HTR4HTR3A | |
| SCHEMBL19902334 | 0.71 | ALDH1A1 (0.57) | ROCK1ROCK2HTR4HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | ROCK1 1/4885ROCK2 3/4885HTR4 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.